Abemaciclib对利伐沙班的显著影响。

IF 2.8 4区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Therapeutic Drug Monitoring Pub Date : 2025-02-14 DOI:10.1097/FTD.0000000000001301

Xiaoshuang He, Yongjie Ding, Jie Fang, Juntao Zhao, Xiaoli Ma, Fengmei Hu, Qing Qu, Xiaolan Bian, Qiuya Lu

{"title":"Abemaciclib对利伐沙班的显著影响。","authors":"Xiaoshuang He, Yongjie Ding, Jie Fang, Juntao Zhao, Xiaoli Ma, Fengmei Hu, Qing Qu, Xiaolan Bian, Qiuya Lu","doi":"10.1097/FTD.0000000000001301","DOIUrl":null,"url":null,"abstract":"Background: A patient was treated with abemaciclib and rivaroxaban. Therapeutic drug monitoring revealed high total plasma concentrations of rivaroxaban, which was identified as likely cause of abnormal bleeding. This result indicating that it was caused by drug-drug interaction.Methods: According to the pharmacokinetic profile, the concentrations of rivaroxaban, abemaciclib, and its metabolite (M2) were monitored.Results: The concentrations of abemaciclib and its metabolite (M2) decreased with the reduction in rivaroxaban dosage.Conclusions: This case study demonstrates the interactions between abemaciclib and rivaroxaban. For patients with complex medications, therapeutic drug monitoring can reduce the occurrence of adverse effects.","PeriodicalId":23052,"journal":{"name":"Therapeutic Drug Monitoring","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Significant Influence of Abemaciclib on Rivaroxaban.\",\"authors\":\"Xiaoshuang He, Yongjie Ding, Jie Fang, Juntao Zhao, Xiaoli Ma, Fengmei Hu, Qing Qu, Xiaolan Bian, Qiuya Lu\",\"doi\":\"10.1097/FTD.0000000000001301\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: A patient was treated with abemaciclib and rivaroxaban. Therapeutic drug monitoring revealed high total plasma concentrations of rivaroxaban, which was identified as likely cause of abnormal bleeding. This result indicating that it was caused by drug-drug interaction.Methods: According to the pharmacokinetic profile, the concentrations of rivaroxaban, abemaciclib, and its metabolite (M2) were monitored.Results: The concentrations of abemaciclib and its metabolite (M2) decreased with the reduction in rivaroxaban dosage.Conclusions: This case study demonstrates the interactions between abemaciclib and rivaroxaban. For patients with complex medications, therapeutic drug monitoring can reduce the occurrence of adverse effects.\",\"PeriodicalId\":23052,\"journal\":{\"name\":\"Therapeutic Drug Monitoring\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Drug Monitoring\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/FTD.0000000000001301\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Drug Monitoring","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FTD.0000000000001301","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：1例患者接受阿贝马昔lib和利伐沙班联合治疗。治疗药物监测显示利伐沙班总血浆浓度高，这被确定为异常出血的可能原因。这一结果表明它是由药物-药物相互作用引起的。方法：根据药动学特征，监测利伐沙班、阿贝马昔利布及其代谢产物（M2）的浓度。结果：阿贝马昔利布及其代谢产物M2浓度随利伐沙班剂量的减少而降低。结论：本病例研究证明了阿贝马昔lib和利伐沙班之间的相互作用。对于复杂用药的患者，进行治疗性药物监测可以减少不良反应的发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Significant Influence of Abemaciclib on Rivaroxaban.

Background: A patient was treated with abemaciclib and rivaroxaban. Therapeutic drug monitoring revealed high total plasma concentrations of rivaroxaban, which was identified as likely cause of abnormal bleeding. This result indicating that it was caused by drug-drug interaction.

Methods: According to the pharmacokinetic profile, the concentrations of rivaroxaban, abemaciclib, and its metabolite (M2) were monitored.

Results: The concentrations of abemaciclib and its metabolite (M2) decreased with the reduction in rivaroxaban dosage.

Conclusions: This case study demonstrates the interactions between abemaciclib and rivaroxaban. For patients with complex medications, therapeutic drug monitoring can reduce the occurrence of adverse effects.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Therapeutic Drug Monitoring 医学-毒理学

CiteScore

5.00

自引率

8.00%

发文量

213

审稿时长

4-8 weeks

期刊介绍： Therapeutic Drug Monitoring is a peer-reviewed, multidisciplinary journal directed to an audience of pharmacologists, clinical chemists, laboratorians, pharmacists, drug researchers and toxicologists. It fosters the exchange of knowledge among the various disciplines–clinical pharmacology, pathology, toxicology, analytical chemistry–that share a common interest in Therapeutic Drug Monitoring. The journal presents studies detailing the various factors that affect the rate and extent drugs are absorbed, metabolized, and excreted. Regular features include review articles on specific classes of drugs, original articles, case reports, technical notes, and continuing education articles.